Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease
- PMID: 34629893
- PMCID: PMC8493111
- DOI: 10.2147/IJGM.S328486
Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Postexposure Prophylaxis of COVID-19 in Hospital Personnel Dedicated to Patients Care with COVID-19 Disease
Abstract
Background: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the treatment of common cold. In vitro, I-C inhibits SARS-CoV-2 infection in cell culture.
Research question: Can a nasal spray with Iota-Carrageenan be useful in the prophylaxis of COVID-19 in health care workers managing patients with COVID-19 disease?
Study design and methods: This is a pilot pragmatic multicenter, randomized, double-blind, placebo-controlled study assessing the use of a nasal spray containing I-C in the prophylaxis of COVID-19 in hospital personnel dedicated to care of COVID-19 patients. Clinically healthy physicians, nurses, kinesiologists and other health care providers managing patients hospitalized for COVID-19 were assigned in a 1:1 ratio to receive four daily doses of I-C spray or placebo for 21 days. The primary end point was clinical COVID-19, as confirmed by reverse transcriptase polymerase chain reaction testing, over a period of 21 days. The trial is registered at ClinicalTrials.gov (NCT04521322).
Results: A total of 394 individuals were randomly assigned to receive I-C or placebo. Both treatment groups had similar baseline characteristics. The incidence of COVID-19 differs significantly between subjects receiving the nasal spray with I-C (2 of 196 [1.0%]) and those receiving placebo (10 of 198 [5.0%]). Relative risk reduction: 79.8% (95% CI 5.3 to 95.4; p=0.03). Absolute risk reduction: 4% (95% CI 0.6 to 7.4).
Interpretation: In this pilot study a nasal spray with I-C showed significant efficacy in preventing COVID-19 in health care workers managing patients with COVID-19 disease.
Clinical trials registration: NCT04521322.
Keywords: COVID-19; hospital workers; nasal; prophylaxis; spray.
© 2021 Figueroa et al.
Conflict of interest statement
Dr Juan Manuel Figueroa report grantfrom Programa de articulación y fortalecimiento federal de las capacidades en ciencia y tecnología COVID-19, Proyecto CABA 20. Ministerio de Ciencia, Tecnología e Innovación, Argentina; Freely provided drug and placebo samples from Laboratorio Pablo Cassará, during the conduct of the study; personal fees from Laboratorio Pablo Cassará, outside the submitted work; Dr Mónica Lombardo report personal fees from Laboratorio Pablo Cassará, outside the submitted work, is a Director of Scientific Affairs at Nobeltri S.R.L; Dr Robert Giugliano report personal fees from Astra Zeneca, personal fees from CVS Caremark, personal fees from Pfizer, personal fees from Novartis, outside the submitted work; and Institutional research grant to the TIMI Study Group at Brigham and Women’s Hospital for research he is not directly involved in from Abbott; Aralez; AstraZeneca; Bayer; Eisai; GlaxoSmithKline; Intarcia; Janssen Research and Development; Medicines Company; MedImmune; Novartis; Poxel; Pfizer; Quark Pharmaceuticals; Roche; Takeda; Zora Biosciences. The authors report no other conflicts of interest in this work.
Figures
Similar articles
-
A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxis-ICE-COVID.Trials. 2022 Sep 15;23(1):782. doi: 10.1186/s13063-022-06685-z. Trials. 2022. PMID: 36109791 Free PMC article.
-
Ivermectin for preventing and treating COVID-19.Cochrane Database Syst Rev. 2022 Jun 21;6(6):CD015017. doi: 10.1002/14651858.CD015017.pub3. Cochrane Database Syst Rev. 2022. PMID: 35726131 Free PMC article. Review.
-
Safety and efficacy of iota-carrageenan nasal spray in treatment and prevention of the common cold.Med Pharm Rep. 2021 Jan;94(1):28-34. doi: 10.15386/mpr-1817. Epub 2021 Jan 29. Med Pharm Rep. 2021. PMID: 33629045 Free PMC article. Review.
-
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9. Trials. 2020. PMID: 33115543 Free PMC article.
-
Lessons learned from a double-blind randomised placebo-controlled study with a iota-carrageenan nasal spray as medical device in children with acute symptoms of common cold.BMC Complement Altern Med. 2012 Sep 5;12:147. doi: 10.1186/1472-6882-12-147. BMC Complement Altern Med. 2012. PMID: 22950667 Free PMC article. Clinical Trial.
Cited by
-
Why Certain Repurposed Drugs Are Unlikely to Be Effective Antivirals to Treat SARS-CoV-2 Infections.Viruses. 2024 Apr 22;16(4):651. doi: 10.3390/v16040651. Viruses. 2024. PMID: 38675992 Free PMC article.
-
Natural products as a source of Coronavirus entry inhibitors.Front Cell Infect Microbiol. 2024 Feb 21;14:1353971. doi: 10.3389/fcimb.2024.1353971. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38449827 Free PMC article. Review.
-
SARS-CoV-2 spike protein-ACE2 interaction increases carbohydrate sulfotransferases and reduces N-acetylgalactosamine-4-sulfatase by p38 MAPK.Signal Transduct Target Ther. 2024 Feb 14;9(1):39. doi: 10.1038/s41392-024-01741-3. Signal Transduct Target Ther. 2024. PMID: 38355690 Free PMC article.
-
From Ocean to Medicine: Harnessing Seaweed's Potential for Drug Development.Int J Mol Sci. 2024 Jan 8;25(2):797. doi: 10.3390/ijms25020797. Int J Mol Sci. 2024. PMID: 38255871 Free PMC article. Review.
-
An Update on the Chemical Constituents and Biological Properties of Selected Species of an Underpinned Genus of Red Algae: Chondrus.Mar Drugs. 2024 Jan 17;22(1):47. doi: 10.3390/md22010047. Mar Drugs. 2024. PMID: 38248672 Free PMC article. Review.
References
-
- Logunov DY, Dolzhikova IV, Shcheblyakov DV, et al.; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled Phase 3 trial in Russia. Lancet. 2021;397(10275):671–681. doi:10.1016/S0140-6736(21)00234-8 - DOI - PMC - PubMed
-
- World Health Organization Draft landscape of COVID-19 candidate vaccines; January22, 2021. Available from:https://www.who.int/publications/m/item/draft-landscape-of-cOVID-19-cand.... Accessed September16, 2021.
Publication types
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous